Early Treatment with Pegylated Interferon
Lambda for Covid-19
BACKGROUND The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear. METHODS We conducted a randomized, controlled, adaptive platform trial involving predominantly vaccinated adults with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brazil and Canada. Outpatients who presented […]
Resilient clinical trial infrastructure in response to the COVID-19 pandemic: Lessons learned from the TOGETHER randomized platform clinical trial
Interferon treatments for SARS-CoV-2: Challenges and opportunities
Evaluating COVID vaccines in the real world
Platform Life Sciences is a rapidly growing global health contract research organization (CRO) specializing in conducting international platform clinical trials for medical interventions.
Early treatment with fluvoxamine among patients with COVID-19: A cost-consequence model
This paper examined the economic impact of the use of fluvoxamine for early treatment in outpatient populations. A cost-consequence analysis was conducted using a decision-model to assess the health system benefits of the avoidance of progression to severe COVID-19. The analysis found that fluvoxamine is cost-saving for COVID-19 outpatient therapy.